Louise Frederika Kooij, Chief Accounting Officer at NewAmsterdam Pharma Co N.V. (NAMS), sold 65,000 shares at $35.69 ($2.3M) on 2026-05-26, disclosed to the SEC on 2026-05-27.
Scheduled sale ($2.3M) by Chief Accounting Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| NAMS | SELL | 2026-01-29 | $2.3M | — | Filing → |
| NAMS | SELL | 2026-01-27 | $2.4M | — | Filing → |
| NAMS | SELL | 2026-01-07 | $88K | — | Filing → |